Los Angeles Capital Management
CTKB icon

Los Angeles Capital Management’s Cytek Biosciences CTKB Stock Holding History

Los Angeles Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,420
Closed -$105K – 2439
2025
Q4 		$105K Buy
+27,420
New +$127K ﹤0.01% 1403
2025
Q3 		– Sell
-15,332
Closed -$52.1K – 1393
2025
Q2 		$52.1K Buy
+15,332
New +$51.1K ﹤0.01% 1302

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Los Angeles Capital Management's CTKB Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 27,420 shares — an estimated $105K sold.

Los Angeles Capital Management first reported a position in CTKB in Q2 2025 and held it in 2 quarters. The position peaked at $105K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 27,420 Cytek Biosciences shares in Q1 2026, an estimated $105K.
  • Los Angeles Capital Management first reported a position in Cytek Biosciences in Q2 2025 and held it in 2 quarters.
  • Los Angeles Capital Management's Cytek Biosciences position peaked at $105K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.